Market Overview

Bank of America Merrill Lynch Reiterates Buy Rating, $100 PT on McKesson Corporation

Related MCK
Who Will Feel The Pain From Generic Drug Price Inflation?
McKesson Launches Venture Fund, Appoints Tom Rodgers As Managing Director

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating and $100.00 price target on McKesson Corporation (NYSE: MCK).

BofA Merrill Lynch noted, “We are ever wary of MCK's capital deployment effort, which has been skewed toward acquisitions across its businesses that call into question the company's ability to earn a return on an expanding intangible asset base. Even so, we still favor MCK and its drug distributor peers as defensive names in equity markets where reimbursement, reform, and debt ceiling concerns are detracting from the allure of health care services stocks. We believe better revenue trends should be a mainstay in the coming quarters, and MCK can pull a number of levers (business mix, economies of scale, and acquisitions and other capital deployment) to top earnings expectations.”

McKesson Corporation closed on Monday at $96.93.

Latest Ratings for MCK

DateFirmActionFromTo
Oct 2014Deutsche BankMaintainsBuy
Oct 2014JP MorganMaintainsOverweight
Sep 2014BarclaysInitiates Coverage onOverweight

View More Analyst Ratings for MCK
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Reiteration Analyst Ratings

 

Related Articles (MCK)

Around the Web, We're Loving...

Get Benzinga's Newsletters